Eurofins Scientific : Credit Presentation May 2021

CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its affiliates. No part of it may be used, circulated, quoted, or reproduced for distribution outside companies belonging to the Eurofins Group. If you are

not the intended recipient of this document, you are hereby notified that the	use,
circulation, quoting,	or reproducing of	this	document is strictly prohibited and	may
be unlawful. Photo	images on this page	are	the copyrighted property of 123RF Limited.
D

Credit Presentation

10 May 2021

www.eurofins.com

Disclaimer

This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on in connection with, any offer or commitment whatsoever.

The statements made during this presentation or as response to questions during the Question & Answers period that are not historical facts are forward looking statements. Furthermore, estimates and judgements may be made based on market and competitive information available at a certain time. Forward looking statements and estimates represent the judgement of Eurofins Scientific's management and involve risks and uncertainties including, but not limited to, risks associated with the inherent uncertainty of research, product/service development and commercialisation, the impact of competitive products and services, patents and other risk uncertainties, including those detailed from time to time in period reports, including prospectus and annual reports filed by Eurofins Scientific with the Luxembourg Stock Exchange and regulatory authorities, that can cause actual results to differ materially from those projected. Eurofins Scientific expressly disclaims any obligation or intention to release publicly any updates or revisions to any forward looking statement or estimate.

Eurofins provides in the Income Statement certain alternative performance measures (non-IFRS information as "Adjusted Results and Separately Disclosed Items") that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. (Please refer to description of these terms in the Company's Annual Report). The management believes that providing this information enhances investors' understanding of the company's core operating results and future prospects, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods or objectives and to the performance of our competitors. This information should be considered in addition to, but not in lieu of, information prepared in accordance with IFRS. These APMs are described in more detail in the Consolidated Financial Statements 2020 in Notes 1.27 and 1.28.

2

Agenda

1. Eurofins at a glance

1. Market & Strategic Positioning

1. Commitment to ESG

IV. Finance & Outlook

1. Contemplated transaction

3

I. Eurofins at a glance

4

Key operational highlights

• Eurofins remained very active in fighting the pandemic throughout Q1 2021:
• • Set up very high throughput SARS-CoV-2 NGS1 capacity and won large contracts to support several countries and institutions to monitor and identify the emergence and spread of new Variants of Interest or of Concern
  • Continued its innovation and product launches, particularly around self-testing
  • Continued expansion of the Group's SAFER@WORK™ offering
• Continued cooperation between business lines to share knowledge and enhance cross selling efforts with, as an example, PFAS2 testing becoming of increasing interest for environmental and food industry
• Strong activity across the Group's diverse Drug Discovery portfolio with strong pick-up in discovery programmes in Q1
• Continued reinforcement of the Group's capabilities in Food and Agriproducts Testing:
• • In Europe, with a start-up laboratory in Lodz, Poland, and a new laboratory in Croatia close to Zagreb
  • In the U.S., with strong volume growth across the entire portfolio
  • Launch of Eurofins' new NGS offer for bacterial flora identification
• Environment Testing business in Australia and New Zealand recovered well in Q1 2021. Strong rebound of North American business in late March
• Continued investments in the Group's laboratory network and IT systems
• Consistent with 2020, M&A has remained deprioritised in Q1 2021, as the Group focuses on responding to COVID-19 and investing in the existing business

1 Next Generation Sequencing	5
2 Per- and polyfluoroalkyl substances